✦ LIBER ✦

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

✍ Scribed by Nigel Bundred, Janis Gardovskis, Janusz Jaskiewicz, Janis Eglitis, Viktor Paramonov, Peter McCormack, Helen Swaisland, Maria Cavallin, Tony Parry, James Carmichael, J. Michael Dixon…show all 11hide

Book ID: 120966759
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 289 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-012-9922-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of the oral PARP inhibitor

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

✍ Dent, Rebecca A; Lindeman, Geoffrey J; Clemons, Mark; Wildiers, Hans; Chan, Arle 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 207 KB

Safety and tolerability of the poly(ADP-

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

✍ Jens Samol, Malcolm Ranson, Edwina Scott, Euan Macpherson, James Carmichael, Ann 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 215 KB

A phase I trial evaluating the safety an

A phase I trial evaluating the safety and immunogenicity of a HER-2 protein vaccine in patients with breast cancer

✍ B Overmoyer; A Brufsky; B Volck; D Leach; A Oestergaard 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Evaluation of safety, pharmacokinetics,

Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial

✍ Toshihiko Doi,Tetsuya Hamaguchi… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 284 KB

288 Pharmacokinetics and pharmacodynamic

288 Pharmacokinetics and pharmacodynamics of the novel proteasome inhibitor CEP-18770 during a phase I trial in patients with solid tumor, non-Hodgkin lymphoma or multiple myeloma

✍ F. Sala; E. Marangon; D. Brunelli; C. Sessa; E. Dall'Ó; R. Cereda; V. Livi; M. D 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

116 A phase I clinical trial to evaluate

116 A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer

✍ K. Vallis; R. Reilley; D. Scollard; J. Petronis; C. Caldwell; A. Hendler; G. Loc 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 122 KB